ZIMV Stock Overview Develops, manufactures, and markets a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for ZimVie Historical stock prices Current Share Price US$13.76 52 Week High US$22.40 52 Week Low US$13.01 Beta 1.98 1 Month Change -2.89% 3 Month Change -13.51% 1 Year Change -23.64% 3 Year Change n/a 5 Year Change n/a Change since IPO -50.86%
Recent News & Updates
ZimVie Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2024 Nov 02
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 01
New minor risk - Share price stability Aug 04
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 02
ZimVie Inc. Reiterates Earnings Guidance for the Full Year Ending December 31, 2024 Aug 02
ZimVie Inc. Announces the Release of RealGUIDE® 5.4 Software Update Jul 31 See more updates
ZimVie Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2024 Nov 02
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 01
New minor risk - Share price stability Aug 04
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 02
ZimVie Inc. Reiterates Earnings Guidance for the Full Year Ending December 31, 2024 Aug 02
ZimVie Inc. Announces the Release of RealGUIDE® 5.4 Software Update Jul 31
ZimVie Inc. Announces FDA Clearance and U.S. Launch of GenTek Restorative Components Jul 23
ZimVie Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 19
Now 31% overvalued after recent price rise Jul 01
Now 42% overvalued after recent price rise Jun 25
Now 21% overvalued Jun 05
ZimVie: Guidance Suggests Company Fairly Valued At The Moment (Rating Downgrade) Jun 04
President exercised options and sold US$356k worth of stock May 20
ZimVie Inc. Provides Earnings Guidance for the Full Year 2024 Ending December 31, 2024 May 10
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 09
ZimVie Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 26
President exercised options and sold US$172k worth of stock Apr 04 H.I.G. Capital, LLC completed the acquisition of Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV). Apr 02
ZimVie Inc., Annual General Meeting, May 15, 2024 Apr 01
ZimVie Inc., Annual General Meeting, May 15, 2024 Mar 30
President exercised options and sold US$163k worth of stock Mar 13
Price target increased by 19% to US$16.00 Mar 04
New minor risk - Shareholder dilution Mar 01
ZimVie Inc. Provides Earnings Guidance for First Quarter and Raises Earnings Guidance for the Full Year 2024 Mar 01
Full year 2023 earnings: EPS misses analyst expectations Feb 29
ZimVie Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 22
ZimVie: Shrinking Its Way To Profitability Feb 12
ZimVie Inc. Announces Launch of Next-Generation TSX®? Implant in Japan Feb 08
H.I.G. Capital, LLC entered into an Equity Purchase Agreement to acquire Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV) for approximately $380 million. Dec 19
ZimVie Inc. (NASDAQ:ZIMV) Stock Catapults 93% Though Its Price And Business Still Lag The Industry Dec 19 H.I.G. Capital, LLC entered into an Equity Purchase Agreement to acquire Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV) for approximately $380 million. Dec 19
ZimVie Inc. Announces Compatibility Between Its Vital Spinal Fixation System and Brainlab Spine & Trauma Navigation Dec 13
Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.032 profit in 3Q 2022) Nov 03
Zimvie Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023 Nov 02
ZimVie Inc. Announces First U.S. Surgery with the 4.5mm Mobi-C(R) Cervical Disc Nov 01
ZimVie Inc. Announces the Launch of Azure Multi-Platform Product Solutions Oct 18
ZimVie Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 12
ZimVie Inc. Announces the Recent Launch of Biotivity A/C Plus Membrane Oct 11
ZimVie Announces FDA Approval to Launch Mobi-C® Hybrid Study Sep 27
ZimVie Inc. Announces FDA Approval for New Mobi-C(R) Implant Aug 11
Second quarter 2023 earnings released: US$0.89 loss per share (vs US$0.33 loss in 2Q 2022) Aug 03
ZimVie Inc. Revises Financial Guidance for the Full Year Ending December 31, 2023 Aug 03
New minor risk - Share price stability Jul 18
ZimVie Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 13
First quarter 2023 earnings released: US$1.14 loss per share (vs US$0.98 loss in 1Q 2022) May 05
Zimvie Inc. Revises Earnings Guidance for the Full Year 2023 May 04
ZimVie Inc.'s (NASDAQ:ZIMV) Shares Bounce 27% But Its Business Still Trails The Industry Apr 17
President recently bought US$122k worth of stock Mar 09
Full year 2022 earnings released: US$2.45 loss per share (vs US$3.66 loss in FY 2021) Mar 03
ZimVie Inc. to Report Q4, 2022 Results on Mar 01, 2023 Feb 14
ZimVie Inc. Announces Over 200,000 Cervical Discs Have Been Replaced with Mobi-C Jan 31
High number of new and inexperienced directors Nov 16
ZimVie Inc. Reaffirms Revenue Guidance for the Year 2022 Nov 10
Zimvie Announces Launch of Next-Generation TSX™ Implant in the United States Nov 04
ZimVie Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 20
Zimvie Expands Navigation-Compatible Platform to Include Posterior Cervical Application Oct 12
ZimVie Inc.(NasdaqGS:ZIMV) dropped from FTSE All-World Index (USD) Sep 19
ZimVie: Disappointing Guidance Prompts Caution Aug 25
Second quarter 2022 earnings released Aug 12
ZimVie Inc. Revises Net Sales Guidance for the Year 2021 Aug 11
ZimVie Q2 Non-GAAP EPS beats, revenue down Y/Y, guidance reduced Aug 10
ZimVie Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 21
ZimVie: Undervalued Spin-Off Jul 05
Zimvie Inc. Announces Launch of Two Next-Generation Dental Solutions in the United States Jun 17
Executive VP recently bought US$205k worth of stock May 11
High number of new and inexperienced directors Apr 28
ZimVie: Spin-Off Of Dental And Spine Units Of Zimmer Biomet Apr 23
ZimVie Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 13
Forecast to breakeven in 2022 Apr 03
ZimVie Inc. Provides Revenue Guidance for the Year Ending December 31, 2022 Apr 01
High number of new and inexperienced directors Mar 11 ZimVie Inc.(NasdaqGS:ZIMV) dropped from S&P 500 Health Care (Sector)
ZimVie Inc.(NasdaqGS:ZIMV) dropped from S&P Global 1200 Mar 04
ZimVie Inc. Announces Board of Directors Mar 03 Shareholder Returns ZIMV US Medical Equipment US Market 7D 0.2% -1.1% -2.2% 1Y -23.6% 10.1% 23.9%
See full shareholder returns
Return vs Market: ZIMV underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is ZIMV's price volatile compared to industry and market? ZIMV volatility ZIMV Average Weekly Movement 3.9% Medical Equipment Industry Average Movement 7.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ZIMV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ZIMV's weekly volatility (4%) has been stable over the past year.
About the Company ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures worldwide. It operates through The Dental Segment. The company offers dental implant systems; biomaterials; prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name.
Show more ZimVie Inc. Fundamentals Summary How do ZimVie's earnings and revenue compare to its market cap? ZIMV fundamental statistics Market cap US$375.34m Earnings (TTM ) -US$47.73m Revenue (TTM ) US$451.29m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ZIMV income statement (TTM ) Revenue US$451.29m Cost of Revenue US$166.17m Gross Profit US$285.13m Other Expenses US$332.85m Earnings -US$47.73m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.73 Gross Margin 63.18% Net Profit Margin -10.58% Debt/Equity Ratio 54.2%
How did ZIMV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 08:11 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ZimVie Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Matt Miksic Barclays Matthew Miksic Credit Suisse null null Equisights
Show 4 more analysts 
